Due to scheduled maintenance work on our servers, there may be short service disruptions on this website between 11:00 and 12:00 CEST on March 28th.
jcm-logo

Journal Browser

Journal Browser

Clinical Prevention and Treatment of Graft-Versus-Host Disease (GVHD)

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: closed (20 October 2025) | Viewed by 626

Special Issue Editor


E-Mail Website
Guest Editor
Servizio di Immunoematologia e Medicina Trasfusionale, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milano, Italy
Interests: graft-versus-host disease (GVHD); hematopoietic stem cell transplantation; immunosuppressive therapy; JAK inhibitors; GVHD biomarkers; transplantation complications
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Graft-versus-host disease (GVHD) is a major complication following allogeneic hematopoietic stem cell transplantation (HSCT), characterized by immune-mediated tissue damage resulting from the recipient’s immune system attacking the donor’s cells. GVHD is classified into acute and chronic forms, with both posing significant risks to patient outcomes, including morbidity, mortality, and long-term health complications. It is a critical challenge in the field of transplant medicine, particularly in the context of improving post-transplant quality of life.

Over the years, advancements in immunosuppressive therapies and post-transplant management strategies have led to a decrease in the incidence and severity of GVHD. Current treatment strategies focus on prevention, early detection, and mitigation of GVHD severity.

This Special Issue on the Clinical Prevention and Treatment of Graft-versus-host disease (GVHD) will focus on the evolving strategies in the prevention and management of GVHD, including novel immunosuppressive regimens, advances in biomarker discovery, and promising therapies. It will also explore the emerging role of post-transplant interventions aimed at reducing chronic GVHD and improving long-term patient survival and quality of life.

Dr. Roberto Crocchiolo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • graft-versus-host disease (GVHD)
  • hematopoietic stem cell transplantation
  • immunosuppressive therapy
  • JAK inhibitors
  • GVHD biomarkers
  • transplantation complications

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

29 pages, 2209 KB  
Review
Current Diagnosis and Management of Ocular Graft-Versus-Host Disease at a Tertiary Cancer Center
by Eesa M. Khattak, Nathan A. Seto, Calvin W. Wong, Rugveda R. Patil, Dan S. Gombos, Joshua L. Olson and Richard W. Yee
J. Clin. Med. 2026, 15(5), 1926; https://doi.org/10.3390/jcm15051926 - 3 Mar 2026
Viewed by 295
Abstract
Ocular graft-versus-host disease (oGVHD) remains one of the most challenging complications of allogeneic hematopoietic stem cell transplantation (HSCT), often leading to severe ocular surface morbidity and irreversible vision loss if not properly managed. Diagnostic uncertainty persists due to variability in clinical presentation and [...] Read more.
Ocular graft-versus-host disease (oGVHD) remains one of the most challenging complications of allogeneic hematopoietic stem cell transplantation (HSCT), often leading to severe ocular surface morbidity and irreversible vision loss if not properly managed. Diagnostic uncertainty persists due to variability in clinical presentation and a lack of universally accepted criteria, but the greatest clinical burden lies in establishing effective, durable treatment protocols. Current strategies range from lubricants and topical immunomodulators to advanced surgical interventions; however, outcomes remain inconsistent due to delayed recognition and heterogeneous practices across institutions. At institutions like MD Anderson Cancer Center (MDACC), a structured treatment strategy has been developed that emphasizes early recognition and targeted therapy based on the specific ocular tissues affected. This approach integrates patient-reported outcomes with objective ocular findings and applies stepwise therapeutic escalation aligned with tissue-specific pathology. This review offers a brief overview of the clinical burden and pathophysiology of oGVHD, outlines the key diagnostic challenges, and a more detailed discussion on therapeutic strategies with particular emphasis on the targeted tissue-based approaches. Full article
(This article belongs to the Special Issue Clinical Prevention and Treatment of Graft-Versus-Host Disease (GVHD))
Show Figures

Figure 1

Back to TopTop